reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advan...

Por Lacouture, M. E.
Publicado no Ann Oncol (2016)

Taking it in the chin: vitamin K1 for the prevention of acneiform rash

Por Lacouture, M E
Publicado no Ann Oncol (2018)

Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis

Por Belum, V. R., Serna-Tamayo, C., Wu, S., Lacouture, M. E.
Publicado no Clin Exp Dermatol (2015)

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

Por McLellan, B., Ciardiello, F., Lacouture, M. E., Segaert, S., Van Cutsem, E.
Publicado no Ann Oncol (2015)

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

Por Dranitsaris, G., Vincent, M. D., Yu, J., Huang, L., Fang, F., Lacouture, M. E.
Publicado em 2012

Post-reconstruction dermatitis of the breast

Por Rosen, A.C., Goh, C., Lacouture, M.E., Mehrara, B.J., Cordeiro, P.G., Myskowski, P.L.
Publicado no J Plast Reconstr Aesthet Surg (2017)

Olmutinib-induced palmoplantar keratoderma

Por Chen, K. L., Cho, Y. T., Yang, C. W., Sheen, Y. S., Liang, C. W., Lacouture, M. E., Chu, C.Y.
Publicado no Br J Dermatol (2017)

Alopecia in patients treated with molecularly targeted anticancer therapies

Por Belum, V. R., Marulanda, K., Ensslin, C., Gorcey, L., Parikh, T., Wu, S., Busam, K. J., Gerber, P. A., Lacouture, M. E.
Publicado no Ann Oncol (2015)

Granuloma annulare associated with immune checkpoint inhibitors

Por Wu, J., Kwong, B.Y., Martires, K.J., Rieger, K.E., Chung, W.H., Iyer, G.V., Lacouture, M.E.
Publicado no J Eur Acad Dermatol Venereol (2017)

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Por Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., Wolchok, J. D.
Publicado no Ann Oncol (2016)

Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors

Por Zarbo, A., Belum, V.R., Sibaud, V., Oudard, S., Postow, M.A., Hsieh, J.J., Motzer, R.J., Busam, K.J., Lacouture, M.E.
Publicado no Br J Dermatol (2017)

Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor

Por Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D., Lacouture, M.E.
Publicado no Eur J Cancer (2016)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Por Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., LeBoeuf, N. R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A. W., Skondra, D., Suarez-Almazor, M. E., Wang, Y., Wiley, K., Kaufman, H. L., Ernstoff, M. S.
Publicado no J Immunother Cancer (2017)